Oesophageal squamous cell carcinoma stage II – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:43 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Oesophageal squamous cell carcinoma stage II – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Nivolumab or Placebo for Patients with Removed Esophageal or Gastroesophageal Junction Cancer https://clinicaltrials.eu/trial/study-of-nivolumab-or-placebo-for-patients-with-removed-esophageal-or-gastroesophageal-junction-cancer/ Wed, 29 Apr 2026 14:47:49 +0000 https://clinicaltrials.eu/trial/study-of-nivolumab-or-placebo-for-patients-with-removed-esophageal-or-gastroesophageal-junction-cancer-2/ This clinical trial is focused on studying the effects of a treatment called nivolumab on patients who have had surgery to remove esophageal cancer or gastroesophageal junction cancer. These types of cancer occur in the tube that connects the throat to the stomach and the area where the esophagus meets the stomach. The study involves patients who have undergone surgery after receiving chemotherapy and radiation therapy before the operation. The purpose of the study is to compare how well patients do without the cancer coming back when treated with nivolumab compared to a placebo.

Nivolumab, also known by its code name BMS-936558, is given as an infusion, which means it is administered directly into the bloodstream through a vein. The study will observe patients over a period to see if the cancer returns or if they remain disease-free. The main goal is to see how long patients can live without the cancer coming back, which is referred to as disease-free survival. Additionally, the study will look at overall survival, which is the length of time patients live after starting the study, regardless of whether the cancer returns.

Participants in the study will receive either nivolumab or a placebo, and neither the patients nor the researchers will know which treatment each patient is receiving. This is known as a double-blind study, which helps ensure that the results are not influenced by expectations about the treatment. The study aims to provide valuable information on whether nivolumab can help prevent the return of esophageal or gastroesophageal junction cancer after surgery.

]]>